• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 10 (7), 2014
  3. 345-356
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

International Journal of Pharmacology

Year: 2014 | Volume: 10 | Issue: 7 | Page No.: 345-356
DOI: 10.3923/ijp.2014.345.356

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 66

Authors


Hadi Mirfazaelian

Country: Iran

Shekoufeh Nikfar

Country: Iran

Amir-Ahmad Salarian

Country: Iran

Mohammad Abdollahi

Country: Iran

Keywords


  • meta-analysis
  • Organophosphorus
  • oxime
  • poisoning
Review Article

An Updated Meta-Analysis on the Efficacy of Oximes in Acute Human Organophosphorus Poisoning

Hadi Mirfazaelian, Shekoufeh Nikfar, Amir-Ahmad Salarian and Mohammad Abdollahi
The present study is a meta-analysis on clinical trials evaluating the efficacy of oximes on organophosphorus (OP) intoxication treatment. PubMed, Scopus, Google Scholar and clinicaltrials.gov were searched for studies investigating the effects of oximes in the treatment of OP poisoning. Mortality, intermediate syndrome, Intensive Care Unit (ICU) admission rate, hospital stay duration and intubation rate were the key outcomes of interest. Data were searched in the time period of 1966 through April 2014. Thirteen studies (eleven clinical trials and two historical cohorts) that met our criteria were included in the analysis. Pooling of data showed that Relative Risk (RR) of need for intubation in OP poisoning for ten included trials comparing oximes with placebo was 1.18 with 95% CI = 0.76 to 1.84 (p = 0.27). RR of the single observational study was 1.57 (95% CI = 0.79 to 3.2, p>0.05). The summary of RR for mortality rate in 11 studies was 1.4 (95% CI = 0.77 to 2.54, p = 0.41) and for two observational studies was 1.19 (95% CI = 0.5 to 2.85, p>0.05). The RR for ICU admission rate in OP poisoning for three trials comparing oximes to placebo was 2.12 with 95% CI = 0.89 to 5.03 (p = 0.09). For the single observational study, RR was 0.81 (95% CI = 0.49 to 1.25, p>0.05). For intermediate syndrome while the RR of only trial comparing oximes with placebo was 1.89 (95% CI = 1.27 to 2.91, p<0.05), for the single observational study, it was 1.43 (95% CI = 0.7 to 2.96, p>0.05). For hospital stay duration (difference), the RR of four studies was 0.75 with 95% CI = -0.51 to 1.99. According to these data, oximes beneficence in OP poisoning is unclear and there is a potential increase in the incidence of intermediate syndrome.
PDF Fulltext XML References Citation

How to cite this article

Hadi Mirfazaelian, Shekoufeh Nikfar, Amir-Ahmad Salarian and Mohammad Abdollahi, 2014. An Updated Meta-Analysis on the Efficacy of Oximes in Acute Human Organophosphorus Poisoning. International Journal of Pharmacology, 10: 345-356.

DOI: 10.3923/ijp.2014.345.356

URL: https://scialert.net/abstract/?doi=ijp.2014.345.356

Related Articles

Efficacy of Plasma Transfusion in Acute Human Organophosphorus Poisoning: A Systematic Review and Meta-analysis

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved